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Abstract
The 3-O-sulfonation of glucosamine residues in heparan sulfate (HS) by 3-O-sulfotransferase (3-
OST) is a key substitution that is present in HS sequences of biological importance, in particular
HS anticoagulant activity. Six different isoforms of 3-OST have been identified that exhibit
different substrate specificity. In this paper the affinity and kinetics of the interaction between 3-
O-sulfotransferase isoform 1 (3-OST-1) and HS have been examined using surface plasmon
resonance (SPR). 3-OST-1 binds with micomolar affinity to HS (KD= 2.79 µM), and this
interaction is apparently independent of the presence of the coenzyme, 3′-phosphoadenosine 5′-
phosphosulfate (PAPS). A conformational change in the complex has also been detected,
supporting data from previous studies. Selected 3-OST-1 mutants have provided valuable
information of amino acid residues that participate in 3-OST-1 interaction with HS substrate and
its catalytic activity. The results from this study contribute to understanding the substrate
specificity among the 3-OST isoforms and in the mechanism of 3-OST-1-catalyzed biosynthesis
of anticoagulant HS.
Heparan sulfate proteoglycans (HSPGs)1 are protein–carbohydrate conjugates present in the
extracellular matrix and surface of most mammalian cells. HSPGs participate in a diverse
number of biological processes including blood coagulation, viral infection, cell growth and
development, tumor metastasis, and angiogenesis (1–5). They are comprised of one or more
heparan sulfate (HS) glycosaminoglycan chains covalently attached to a core protein (1, 6).
These HS chains bind to numerous proteins and are, thus, responsible for most of the
biological functions of HSPGs (7, 8). HS are highly sulfated, linear polysaccharides
comprised of a repeating disaccharide unit of sulfated β-D-glucuronic/α-L-iduronic acid 1→4-
linked to α-D-glucosamine residues. Sulfo groups can be present in the 2-O-position of the
uronic acid and the 2-N-, 6-O-, and 3-O-positions of the glucosamine residues. Structural
†This work is supported in part by NIH Grants HL52622, HL62244, and GM38060 (to R.J.L.) and AI 50050 (to J.L.). D.X. is a
recipient of a predoctoral fellowship from the American Heart Association MidAtlantic Affiliate.
© 2006 American Chemical Society
*To whom correspondence should be addressed. Phone: (518) 276-3404. Fax: (518) 276-3405. linhar@rpi.edu.
‡Rensselaer Polytechnic Institute.
§University of North Carolina.
1Abbreviations: HSPGs, heparan sulfate proteoglycans; HS, heparan sulfate; PAPS, 3′-phosphoadenosine 5′-phosphosulfate; HSV,
herpes simplex virus; 3-OST, 3-O-sulfotransferase; PAP, 3′-phosphoadenosine 5′-phosphate; SPR, surface plasmon resonance; SA,
streptavidin; FC, flow cell; ITC, isothermal titration calorimetry;
NIH Public Access
Author Manuscript
Biochemistry. Author manuscript; available in PMC 2014 August 12.
Published in final edited form as:






















variations in HS lead to the presence of specific and often rare saccharide sequences within
HS that determine the specificity and protein binding properties of HS (8). HS is initially
synthesized in the Golgi as a copolymer of glucuronic acid and N-acetylglucosamine
attached to a linkage region within its core protein. Subsequent structural modifications are
achieved through the action of a series of biosynthetic enzymes that are believed to act in a
sequential manner. The N-deacetylase N-sulfotransferase catalyzes N-deacetylation/N-
sulfation of glucosamine residues. The C5 epimerase converts glucuronic acid into iduronic
acid followed by O-sulfonation of the 2-O-position of the uronic acid and the 6-O- and 3-O-
positions of the glucosamine unit, catalyzed by 2-OST, 6-OST, and 3-OST, respectively (9).
The actions of these biosynthetic steps are often incomplete, resulting in a large number of
permutations in the sequence of HS.
Sulfotransferases transfer the sulfuryl group from the donor PAPS to specific positions of
the uronic acid and glucosamine residues (Figure 1A). While there is only a single 2-OST,
there are two isoforms of 6-OST and seven isoforms of 3-OST (10). The large number of 3-
OST isoforms is of particular interest since 3-O-sulfonation represents the final modification
step in HS biosynthesis. Moreover, while the 3-O-sulfo group is only infrequently present in
HS, it is a key substitution in important biological processes involved in blood
anticoagulation, HSV infection, regulation of circadian rhythms, and various human cancers
(11–13). The seven different 3-OST isoforms are believed to exhibit both tissue expression
patterns (14) and different substrate specificity (15, 16). As a consequence, different
isoforms are involved in the biosynthesis of different 3-O-sulfo groups containing HS
sequences that can exhibit specific biological functions. The 3-OST-1 and 3-OST-5 isoforms
are involved in the biosynthesis of the pentasaccharide sequence within HS that binds
antithrombin (14, 17–19). The 3-OST-3, 3-OST-5, and 3-OST-6 generate a critical 3-O-
sulfo group present in the HS sequence that binds HSV-1 glycoprotein gD (10, 12, 17, 20).
Thus, the biosynthesis of specific 3-O-sulfo groups containing HS sequences is presumably
regulated by both the specificity of the cell and tissue expression of the 3-OST isoforms as
well as by their defined substrate specificities. The mechanism that underlies the specificity
of the different 3-OST isoforms is unknown.
Over the past several years, studies from our laboratory and others have been published on
3-OST substrate specificity (19, 21–25). In these studies, some structural characteristics of
the HS oligosaccharides that are selectively recognized by 3-OST-1, 3-OST-3, and 3-OST-5
have been elucidated. We have recently reported the crystal structure of 3-OST-3 in a
ternary complex of a tetrasaccharide substrate and PAP (Figure 1B), the product formed
after sulfuryl transfer takes places from PAPS (26). This work afforded structural
information at the atomic level of the ternary complex and provided new insights into HS
substrate recognition. This structural information, together with the crystal structure of 3-
OST-1 in a binary complex with PAP (27), is being used to develop an improved
understanding of the mechanism of action of the entire 3-OST family through structure-
based homology modeling studies (28). On the basis of these studies, the PAP and HS
substrate binding sites in 3-OST-1 were predicted and a number of amino acid residues
relevant for the enzymatic process were proposed, and site-directed mutagenesis revealed
residues that were important for the binding of the enzyme to PAPS. As part of our
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continuing study, we report HS binding analysis of the wild-type 3-OST-1 and selected 3-
OST-1 mutants using SPR. This study provides valuable information on amino acid residues
that are involved in HS substrate binding and the catalytic mechanism of 3-OSTs.
EXPERIMENTAL PROCEDURES
Materials
[35S]PAPS was prepared by incubating 0.4–2 mCi/mL [35S]Na2SO4 (carrier-free, MP
Biomedical) and 16 mM ATP with 5 mg/mL dialyzed yeast extract (Sigma), following a
protocol described by Bame and Esko (29). HS from bovine kidney was purified in our
laboratory. PAP was purchased from Sigma. Porcine intestinal heparan sulfate (14.8 kDa)
and dermatan sulfate (30 kDa) were from Celsus (Cincinnati, OH). Chondroitin sulfate A
(20 kDa, bovine trachea), chondroitin sulfate C (20 kDa, shark cartilage), hyaluronic acid
(100 kDa, Streptococcus zooepidemicus), and Triton X-100 were from Sigma (St. Louis,
MO). Sulfo-N-hydroxysuccinimide long-chain biotin was from Pierce (Rockford, IL).
Streptavidin (SA) sensor chips, sodium acetate (pH = 4.5), and HBS-EP buffer (0.01 M
HEPES, pH = 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% surfactant P20) were from BIAcore
(Biacore AB, Uppsala, Sweden). Phosphate running buffer (0.1 M sodium phosphate, pH =
7.0, 0.1 M NaCl, 0.1% Triton X-100) was prepared for SPR studies from monobasic and
dibasic phosphate (Mallinckrodt) and doubly distilled water. All of the buffers were filtered
(0.22 µm) and degassed prior to use. SPR measurements were performed on a BIAcore 3000
instrument with BIAcore 3000 control and BIAevaluation software (version 4.0.1).
Methods
Expression and Purification of Wild-Type 3-OST-1 and 3-OST-1 Mutants—The
preparations of the expression plasmids are described elsewhere (27). Expression of wild-
type mouse 3-OST-1 and 3-OST-1 mutants was carried out in Rosetta 2 cells (Novagen).
Briefly, Rosetta 2 cells containing the 3-OST-1-pET28 were grown in LB media with 15
µg/mL kanamycin and 35 µg/mL chloramphenicol at 37 °C. When the A600 reached 0.6–0.8,
IPTG was then added to a final concentration of 0.2 mM, and the cells were allowed to
shake overnight at 22 °C. Cells were pelleted and resuspended in the sonication buffer
containing 25 mM Tris, pH 7.5, 500 mM NaCl, and 20 mM imidazole. Cells were disrupted
by sonication and then spun down. The supernatant was applied to a Ni–Sepharose 6 fast-
flow column (1 ×10 cm; Amersham) and washed with the sonication buffer. The bound
protein was eluted with an imidazole gradient from 20 to 250 mM in 100 mL at a flow rate
of 4 mL/min. The purified protein migrated at 33 kDa on 12% SDS–PAGE with the purity
greater than 95%. The concentration of the protein was determined by the BCA kit (Sigma).
The specific enzymatic activity of wild-type 3-OST-1 was determined to be 14 pmol of
sulfate/µg.
Because the 3-OST-1 mutants are catalytically inactive proteins, it is not possible to follow
the enzymatic activity as described below during the purification. The procedure for the
expression and purification of these mutant proteins followed the identical one that was used
for the wild-type protein. The migration profiles of the purified mutants were identical to
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that of wild-type 3-OST-1 on SDS–PAGE and showed greater than 95% purity. The specific
activity of 3-OST-1 E90Q and 3-OST-1 R276A is less than 0.14 pmol/µg.
Determination of the Activity of the Wild-Type 3-OST-1—Recombinant wild-type
3-OST-1 (0.5 µg) was mixed with 1 µg of HS (from bovine kidney) in a buffer containing
[35S]-PAPS (1 ×106 cpm), 50 mM MES, 10 mM MnCl2, 5 mM MgCl2, and 1% Triton
X-100 (pH 7) and 0.1 mg/mL bovine serum albumin. The reaction was incubated at 37 °C
for 1 h and was then subjected to a 200 µL DEAE-Sepharose column (0.5 ×1 cm) to purify
[35S]HS (30). The amount of [35S]HS was proportional to the concentration of 3-OST-1 in
the reaction. Wild-type 3-OST-1 (10 µg) typically affords 2.8 × 106 cpm of [35S]HS, which
is about 1000-fold above the background. The “inactive” mutants used in this study have 1%
or less of the wild-type activity.
Preparation of the HS Sensor Chip—HS was attached to the SA sensor chip surface
by noncovalent capture of biotin to streptavidin. The biotinylated HS was prepared by
reaction of sulfo-N-hydroxysuccinimide long-chain biotin with free amino groups of
unsubstituted glucosamine residues in the polysaccharide chain following a published
procedure (30). A solution of the HS–biotin conjugate (0.1 mg/mL) in HBS-EP running
buffer was injected over flow cell 2 (FC2) or FC4 of the SA chip at a flow rate of 5 µL/min
and 25 °C. A manual injection mode was used, and the immobilization of the ligand to the
surface was monitored as a function of time (sensorgram). HS surfaces were created with
1390 and 479 RU immobilization levels in FC2 and FC4, respectively. FC1 and FC3,
without HS, served as control.
Binding Study of the Interaction of Wild-Type 3-OST-1 and 3-OST-1 Mutants
with HS—A solution of the protein (950 nM) in phosphate running buffer was injected over
FC1 (control) and FC2 (1390 RU in HS) of the SA sensor chip (flow rate = 40 µL/min, T =
25 °C). A kinetic injection mode was used, flowing the protein for 3 min and monitoring the
dissociation for another 3 min. The response was monitored as a function of time, and after
each analyte injection the surface was regenerated with 1 min injection of 2 M NaCl
followed by 1 min injection of sodium acetate (pH = 4.5). The response in FC1 was
subtracted from the response in FC2, and the resulting sensorgrams were analyzed with
BIAevaluation software.
Affinity and Kinetic Analysis of the Interaction of Wild-Type 3-OST-1 and 3-
OST-1–PAP E90Q and R276A Mutants with HS—Wild-type 3-OST-1, E90Q, or
R276A was injected at different concentrations (250, 500, 750, 950, 1500, and 2000 nM) in
phosphate running buffer over FC3 (control) and FC4 (479 RU in HS) of the SA sensor chip
(flow rate = 40 µL/min, 25 °C). For the interaction of 3-OST-1–PAP with HS, phosphate
running buffer containing PAP (40 µM) was used to prepare the analyte solutions. A kinetic
injection mode was used, flowing the protein for 3 min and monitoring the dissociation for
another 3 min. The response was monitored as a function of time, and after each analyte
injection the surface was regenerated with 1 min injection of 2 M NaCl followed by 1 min
injection of sodium acetate (pH = 4.5). The response in FC3 was subtracted from the
response in FC4, and the resulting sensorgrams were analyzed with BIAevaluation software.
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Variable Contact Time Experiment of the Interaction of 3-OST-1 with HS—A
solution of 3-OST-1 (950 nM) in phosphate running buffer was injected at different injection
times (30, 60, 120, 180, and 300 s) over FC1 (control) and FC2 (1390 RU in HS) of the SA
sensor chip. A kinetic injection mode was used, flowing the protein for 30, 60, 120, 120,
180, or 300 s and monitoring the dissociation for 3 min. The response was monitored as a
function of time, and after each analyte injection the surface was regenerated with 1 min
injection of 2 M NaCl followed by 1 min injection of sodium acetate (pH = 4.5). The
conformational change that occurs in the complex was examined by comparison of the
dissociation phase of the normalized sensorgrams. The response in FC1 was subtracted from
the response in FC2, and the resulting sensorgrams were analyzed with BIAevaluation
software.
Solution Competition SPR Study—To perform solution competition SPR studies, 3-
OST-1 (500 nM) was premixed with different concentrations of heparin (1 nM–1 µM), HS
(10 nM–10 µM), dermatan sulfate, chondroitin sulfate A, and chondroitin sulfate C (500
nM–10 µM), and hyaluronic acid (500 nM–1 µM) in phosphate running buffer and injected
over a HS chip (flow rate of 40 µL/min, 25 °C). A kinetic injection mode was used to
monitor the association for 3 min and the dissociation for another 3 min. The surface was
regenerated with consecutive 1 min injections of 50 mM NaOH, 1 M NaCl, and 2 M NaCl.
For each set of glycosaminoglycans a control injection, with only 3-OST-1, was performed
to ensure the surface remained active. The maximum response units were used for the IC50
calculation (31).
RESULTS
SPR Affinity and Kinetic Analysis of the Interaction of 3-OST-1 with HS
The binding between 3-OST-1 and HS was examined by SPR. Biotinylated HS was
immobilized to a SA sensor chip (FC4, 479 RU), and the enzyme in phosphate running
buffer was injected at different concentrations (250–2000 nM) over the HS surface. The
response obtained in the control flow cell (FC3) represented less than 5% of the overall
response from the interaction of 3-OST-1 with HS in FC4. Attempts to fit the sensorgrams
to a simple 1:1 Langmuir binding equation failed. A good fit of the experimental data was
achieved only when a two-state reaction model was used (Figure 2A). This model considers
a 1:1 binding of the analyte to the immobilized ligand followed by a conformational change
in the complex. The two-state reaction model is described in eq 1, where kon and koff are the
on and off rate constants of the binding process between ligand and analyte and k+1 and k−1
are the rate constants of the conformational change.
(1)
The overall dissociation constant (KD) is calculated as KD = (koff/kon)(k−1/k+1). Global
fitting of the sensorgrams provided on and off rate constants of the binding and the
conformational change equilibrium from which a KD of 2.79 µM was calculated (Table 1).
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Additional information of the conformational change was achieved with an experiment that
varied the contact time between ligand and analyte. In this experiment, 3-OST-1 (950 nM)
in phosphate running buffer was injected over the HS surface at different injection times (30,
60, 90, 180, and 300 s). Longer dissociation times allow the conformational change to take
place in a greater extent, generating a more stable conformation, and is reflected in a slower
dissociation rate. The resulting sensorgrams were normalized, and the dissociation phase of
each was compared. The interaction between 3-OST-1 and HS shows a slower dissociation
phase when longer association times are used (Figure 2B). These results are consistent with
a conformational change in 3-OST-1 occurring after binding to HS.
The binding of 3-OST-1 with HS was also investigated in the presence of PAP. PAP is the
product formed when PAPS transfers its sulfuryl group. PAP has a similar affinity to 3-
OST-1 as PAPS and is chemically more stable than PAPS (32). The dissociation constant of
PAP with wild-type 3-OST-1 has been determined by isothermal titration calorimetry (ITC)
to be 14 ± 4 µM (27). This value is similar to the Km value of 10 µM for PAPS with 3-
OST-1 (33), suggesting that the PAP represents a good model for PAPS in studying the
binding affinity to 3-OST-1. To measure the interaction of the binary complex 3-OST-1-
PAP with HS, 3-OST-1 in phosphate running buffer containing an excess amount of PAP
(40 µM) was injected over an HS sensor chip (FC4) at different concentrations (250–2000
nM). The sensorgrams were very similar to the sensorgrams observed for the interaction
between 3-OST-1 and HS in the absence of PAP, and global fitting of the curves to a two-
state reaction model gave comparable binding information (Table 1). This experiment
suggests that the binding of 3-OST-1 to the HS substrate is independent of the interaction
between 3-OST-1 and PAPS.
Selectivity of 3-OST-1 for Substrate Binding
Solution competition studies for 3-OST-1 interaction with various glycosaminoglycans were
next undertaken. In phosphate running buffer 3-OST-1 was mixed with a range of
glycosaminoglycan concentrations, flowed over a HS chip, and the IC50 for each interaction
was estimated (31). Both HS and heparin are 3-OST-1 substrates. Soluble HS competed well
with immobilized HS, giving an IC50 of ~1 µM, but heparin bound considerably more
tightly with an IC50 of ~10 nM. Both chondroitin sulfate A and dermatan sulfate showed
less binding avidity (IC50 ~10 µM) than either of the 3-OST-1 substrates. Neither
chondroitin sulfate C nor hyaluronic acid interacted with 3-OST-1 over the range of
concentrations examined. Finally, chondroitin sulfate C, dermatan sulfate, and hyaluronic
acid (0.5 mg/mL) failed to inhibit 3-OST-1-catalyzed sulfonation of HS in enzyme assays,
whereas chondriotin sulfate A (0.5 mg/mL) inhibits 15% of 3-OST-1 activity.
SPR Binding Analysis of the Interaction of Wild-Type 3-OST-1 and 3-OST-1 Mutants with
HS
The crystal structure of 3-OST-1 in a binary complex with PAP has been reported (27). In
this work a careful analysis of the 3-OST-1–PAP complex was carried out, and a prediction
of residues that are involved in the enzymatic activity was proposed (27). On the basis of
this analysis a total of 18 point mutants of 3-OST-1 were prepared, and the enzymatic
activity of these mutants was examined. Several point mutations abolished or significantly
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reduced the enzymatic activity, suggesting that these amino acids participate in the catalytic
reaction or in the binding to PAPS or HS. The elucidation of residues involved in the
binding of 3-OST-1 to PAPS was carried out by isothermal titration calorimetry binding
studies of selected 3-OST-1 mutants with PAP. To extend this work, we conducted HS
binding studies on a select group of 3-OST-1 mutants using SPR to detect amino acids
residues involved in the interaction between the enzyme and substrate. Six point mutants
were selected with mutations in positions R72, R67, K68, E90, K123, and R276 of the wild-
type protein. Previous activity assays demonstrated that these mutants lack enzymatic
activity (27). R72, R67, K68, K123, and R276 are basic arginine/lysine residues located in a
large open cleft of 3-OST-1 that is believed to be the HS binding site (Figure 3). These
residues probably assist in the binding with HS, interacting with negatively charged sulfo or
carboxyl groups on the substrate. In the mutants studied (R72E, R67A, K68A, K123A, and
R276A) these basic residues were substituted with neutral or acidic amino acids. E90 has
been proposed to be the catalytic base responsible for 3-OST-1 activity (27).
The ability of the six 3-OST-1 mutants to bind HS was examined. A solution of the mutant
(950 nM) in phosphate running buffer was injected over the HS sensor chip (FC2 and FC1
control). No response was observed when R72E, R67A, K68A, and K123A mutants were
injected over the HS surface, demonstrating that these residues are essential for the binding
of 3-OST-1 with HS. Mutants R276A and E90Q bound HS, but the resulting sensorgrams
showed remarkable differences with the sensorgram of the interaction of the wild-type 3-
OST-1 with HS (Figure 4). These data suggest that while amino acids R276 and E90 are not
critical residues for the interaction of the enzyme with the substrate, these mutations
influence the binding. A more detailed binding analysis of these mutants with HS was
required to obtain further insight into the role of these residues in the 3-OST-1/HS
interaction.
The binding affinity and kinetics of the interaction of the two mutants with HS were next
carried out. R276A or E90Q 3-OST-1 mutant was injected at different concentrations (250–
2000 nM) in phosphate running buffer over the HS sensor chip (FC4 and FC3 control). The
best fit of the sensorgrams obtained was achieved when a two-state reaction model was used
for both 3-OST-1 mutants. The affinity and kinetic constants of the interaction were
obtained by individual fitting of the sensorgrams derived from different analyte
concentrations. The final data are given as the average of the individual data accompanied
by the standard error (Table 1). Global fitting of the sensorgrams yielded higher χ2 values
(data not shown).
R276A 3-OST-1 mutant binds HS with lower affinity (KD= 7.13 µM) compared to the wild-
type 3-OST-1 (KD= 2.79 µM). Comparison of the rate constants derived from the fitting
shows that the complex 3-OST-1 R276A mutant–HS dissociates faster (koff= 15.43 × 10−2
s−1) than the 3-OST-1–HS complex (koff= 5.96 × 10−2 s−1). These data demonstrate that the
R276A residue is establishing a secondary interaction with HS that contributes to the
stabilization of the enzyme–substrate complex; nevertheless, this secondary interaction is
not essential for binding.
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The 3-OST-1 E90Q mutant binds HS (KD= 2.51 µM) with the same affinity as the wild-type
3-OST-1 (KD = 2.79 µM), suggesting that E90 is not directly involved in the binding of 3-
OST-1 with HS. The mutation does not affect the rate constants associated with the
conformational change (k+1 and k−1) but accelerates both on and off rate constants of the
binding process by an order of magnitude (Table 1).
DISCUSSION
The 3-O-sulfonation of glucosamine residues in HS is a rare substitution that is present in
HS oligosaccharide sequences of biological importance (34). The HS substrate used in this
study contained no detectable 3-O-sulfo groups. Furthermore, monosaccharide analysis
showed that the hexosamine component of this HS was 79% GlcNAc, 16% GlcNS, 4%
GlcNAc6S, and 1% GlcNS6S and the uronic acid component was 72% GlcA, 27% IdoA,
and 1% IdoA2S (35). The biosynthesis of the 3-O-sulfo group containing HS is a highly
controlled biosynthetic step conducted by seven 3-OST isoforms that establish the structure
of the HS product (10). An understanding of the substrate specificity of this reaction is
important for the control of the biosynthesis of 3-O-sulfo group containing HS sequences
having biologically significant activities. Both HS and heparin bind to 3-OST-1 and serve as
substrates. Other glycosaminoglycans either fail to bind or bind less tightly than do these
substrates. The PAPS coenzyme binding site is conserved among the sulfotransferases.
However, the HS substrate binding site in 3-OST appears to contain structural variations that
might alter its topology, serving as a tool for the selective recognition of specific HS
substrates by different 3-OST isoforms. Thus, the elucidation of the binding and structural
properties of the 3-OST–substrate complex is a key step for determining the mechanism of
the substrate specificity among the 3-OST isoforms.
In this paper we present the affinity, kinetic, and structural study of the interaction between
3-OST-1 and HS. Using kinetic data of the substrate–enzyme interaction obtained by SPR, a
dissociation constant of 2.79 µM for the 3-OST-1–HS complex was calculated. The binding
of 3-OST-1 to the substrate seems to be independent of the presence of the coenzyme
(PAPS). A conformational change in 3-OST-1 takes place on complex formation. This
observed conformational change is supported by previous studies that relied on fluorescence
and chemical modification methods (27). To our knowledge, this is the first detailed affinity
and kinetic study of the interaction of 3-OST-1 with HS.
The examination of the 3-OST-1 mutant interaction with HS provides structural information,
revealing amino acid residues that are important for the binding of the enzyme to the HS
substrate. The basic residues R72, R67, K123, and R276 are located in an open cleft that is
proposed to be the HS binding site (Figure 3A). While site-directed mutagenesis of these
residues abolishes the enzymatic activity, these 3-OST-1 mutants retain their ability to bind
PAP (27). Single point mutations R72A, R67A, and K123A result in 3-OST-1 mutants that
are inactive, probably as a result of their inability to bind HS substrate. Consequently, these
amino acids form part of the HS binding site in 3-OST-1 that is essential for polysaccharide
substrate binding. The R276A mutant binds HS but with lower affinity than wild-type 3-
OST-1 (Table 1). This decrease in binding affinity is due to a faster dissociation of the
enzyme from the HS substrate. These data demonstrate that R276 stabilizes the interaction
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of 3-OST-1 with HS, most probably through an electrostatic interaction with a sulfo group in
the HS substrate. However, this interaction plays a secondary role and is not essential for the
binding. Surprisingly, the R276A mutant lacks of enzymatic activity, suggesting that R276
participates in the catalytic activity of the enzyme. This is supported by the proximity of
R276 to PAP observed in the crystal structure of the 3-OST-1–PAP binary complex (Figure
3B). The K68A mutant partially retains PAP binding but has no enzymatic activity,
suggesting that K68 is involved in the binding to PAPs; however, in the crystal structure of
the 3-OST-1–PAP binary complex K68 is pointing outward toward the HS binding site (27)
(Figure 3B). Binding studies on the K68A mutant 3-OST-1 with HS demonstrate markedly
reduced substrate binding. The involvement of K68 in binding both PAP and HS suggests
that this residue is involved in catalysis.
E90 is a conserved residue that is found on the inside of the large cleft and is proposed as the
catalytic base for the activity of 3-OST-1. Mutation at E90 does not affect 3-OST-1 affinity
for PAP (27) nor does it impact HS binding but instead results in a complete loss of
enzymatic activity, supporting the current hypothesis that E90 is the catalytic base for 3-
OST-1 activity.
In summary, we provide affinity and kinetic data of the interaction of 3-OST-1 with HS and
additional proof of a conformational change that takes place on complex formation. This
study provides valuable information with important implications for understanding the
mechanism of the enzyme/substrate recognition and the catalytic activity of 3-OST-1.
Comparison of the binding properties of the wild-type 3-OST-1 and selected mutants has
identified amino acid residues critical in substrate binding and for catalytic activity,
particularly E90, which we suggest is the catalytic base required for 3-OST-1 activity.
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(A) Schematic of 3-O-sulfonation of HS by 3-OST-1. After formation of the ternary
complex PAPS–3-OST–HS the enzyme transfers the sufo group (●) from the sulfuryl donor
PAPS to the HS polysaccharide substrate. (B) A ternary complex PAP–3-OST–HS is
formed, but PAP lacks a sulfo group to transfer so no catalysis results.
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(A) Sensorgrams of the interaction of 3-OST-1 (250, 500, 750, 950, 1500, and 2000 nM)
with HS. Global fitting of the sensorgrams to a two-state reaction model (curves in red) was
achieved. (B) Sensorgrams of the interaction between 3-OST-1 and HS using different
injection times (30, 60 90, 180, and 300 s). For a better comparison the curves have been
normalized and aligned to the end point of the injection.
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(A) Ribbon diagram of the crystal structure of the binary complex 3-OST–PAP. The amino
acids that have been mutated for the structural analysis of the 3-OST-1–PAP interaction are
highlighted (CPK). (B) PAP and amino acid residues mutated. The figure shows the relative
position of the amino acids with respect to the PAP coenzyme.
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Sensorgrams of the interaction of 3-OST-1, R276A, and E90Q (950 nM) with HS.
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Table 1
SPR Affinity and Kinetic Data of the Interaction of 3-OST-1, 3-OST-1-PAP, R276A, and E90Q with HS
kona (×104 M−1 s−1) koffa (×10−2 s−1) K+1b (×10−3 s−1) K−1b (×10−3 s−1) KD (µM) χ
2
3-OST-1 vs HS 1.46 ± 0.02 5.40 ± 0.07 3.20 ± 0.03 2.41 ± 0.04 2.79 52.5
3-OST-1–PAP vs HS 1.31 ± 0.05 6.0 ± 0.2 4.9 ± 0.1 4.7 ± 0.5 4.4 4.7
R276A vs HS 1.1 ± 0.4 15 ± 3 6 ± 2 2.64 ± 0.01 7
E90Q vs HS 15 ± 2 38 ± 5 2.5 ± 0.6 2.3 ± 0.2 2.5
a
Kon, Koff: on and off rate constants of the binding step.
b
K+1, K−1: on and off rate constants of the conformational change.
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